Improving the methods for evaluating the safety of psychotropic medications in children and adolescents
暂无分享,去创建一个
J. McCracken | J. Levine | L. Greenhill | L. Scahill | M. Davies | M. Riddle | D. McMahon | P. Fisher | R. Findling | B. Vitiello | H. Abikoff | J. Walkup | J. March | J. Zito | James Robinson | L. Capasso | T. Cooper | J. Fried | M. Labellarte | A. Skrobala | Anne M. Skrobala | Michael J. Labellarte
[1] J. Swanson,et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. , 2001, Pediatrics.
[2] D. Safer,et al. Pemoline hepatotoxicity and postmarketing surveillance. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[3] H. Kraemer,et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[4] F. Benes,et al. Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. , 2000, Cerebral cortex.
[5] K. Goa,et al. Lamotrigine. A review of its use in childhood epilepsy. , 2000, Paediatric drugs.
[6] A. Sadeh,et al. Instability of sleep patterns in children with attention-deficit/hyperactivity disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.
[7] P. S. Jensen. ARE STIMULANTS OVERPRESCRIBED , 2000 .
[8] F. Lynch,et al. Trends in the prescribing of psychotropic medications to preschoolers. , 2000, JAMA.
[9] A. Herbst,et al. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. 1971. , 1999, American journal of obstetrics and gynecology.
[10] M. Boyle,et al. Treatment of attention-deficit/hyperactivity disorder. , 1999, Evidence report/technology assessment.
[11] I. Choonara,et al. Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective study , 1999, Acta paediatrica.
[12] C. Hoven,et al. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.
[13] C. Stein,et al. Making medicines safer--the need for an independent drug safety board. , 1998, The New England journal of medicine.
[14] P. Jensen,et al. Medication development and testing in children and adolescents. Current problems, future directions. , 1997, Archives of general psychiatry.
[15] S. Kumra,et al. Case study: risperidone-induced hepatotoxicity in pediatric patients. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[16] J. Swanson,et al. Case study: adverse response to clonidine. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[17] D. Safer. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. , 1997, Journal of child and adolescent psychopharmacology.
[18] S. Faraone,et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.
[19] R. Barkley,et al. Methylphenidate effects on children with Attention Deficit Hyperactivity Disorder: Self-report of symptoms, side-effects, and self-esteem , 1996 .
[20] G. Koren,et al. Pemoline‐associated fulminant liver failure: Testing the evidence for causation , 1995, Clinical pharmacology and therapeutics.
[21] P. Jensen,et al. Developmental perspectives in pediatric psychopharmacology. , 1995, Psychopharmacology bulletin.
[22] D. Robinson,et al. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines , 1994 .
[23] A. Pakarinen,et al. Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy , 1993 .
[24] N. Ryan,et al. Another sudden death in a child treated with desipramine. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.
[25] W. Pelham. Pharmacotherapy for Children with Attention-Deficit Hyperactivity Disorder. , 1993 .
[26] J. Rabkin,et al. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. , 1992, Journal of clinical psychopharmacology.
[27] B. Spilker. Guide to clinical trials , 1991 .
[28] R. Barkley,et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. , 1990, Pediatrics.
[29] Mark D. Hoover,et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. , 1990, Pediatrics.
[30] D. Hirtz,et al. Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence. , 1990, The New England journal of medicine.
[31] J. Levine. Ascertainment of side effects in psychopharmacologic clinical trials. , 1990, Psychopharmacology series.
[32] W. Maier,et al. Methodology of the Evaluation of Psychotropic Drugs , 1990, Psychopharmacology Series.
[33] F. Dreifuss,et al. Valproic acid hepatic fatalities , 1987, Neurology.
[34] J. Levine,et al. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. , 1986, Psychopharmacology bulletin.
[35] A. Harcus,et al. Post-marketing surveillance of drugs. , 1979, British medical journal.
[36] A. Herbst,et al. ADENOCARCINOMA OF THE VAGINA , 1971 .